Novartis gets final EC nod for Votubia

Novartis ($NVS) has won European approval for Votubia as a treatment for a rare type of brain tumor known as subependymal giant cell astrocytoma associated with tuberous sclerosis complex. With the same active ingredient as the kidney cancer drug Afinitor, Votubia is the first drug approved for these tumors. Release | Report